Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Fluorouracil
66%
Gemcitabine
52%
Cisplatin
40%
Folinic Acid
39%
Biliary Tract Cancer
39%
Neoplasm
38%
Irinotecan
37%
Oxaliplatin
35%
Progression Free Survival
34%
First-Line Chemotherapy
32%
Docetaxel
31%
Non Small Cell Lung Cancer
26%
Anthracycline
19%
Placebo
19%
Breast Cancer
19%
Metastatic Colorectal Cancer
19%
Capecitabine
19%
Phase II Trials
17%
Adenocarcinoma
17%
Survival Rate
17%
Anemia
16%
Taxane
15%
Monotherapy
15%
Neutropenia
14%
Recurrent Disease
13%
Tamoxifen
13%
Janus Kinase 2
13%
Myeloproliferative Disorder
13%
Procedural Pain
13%
Lorazepam
13%
Catenin
13%
Survivin
13%
Angioimmunoblastic T Cell Lymphoma
13%
Cancer of Unknown Primary Site
13%
CA 19-9 Antigen
13%
Lung Cancer
13%
Metastatic Breast Cancer
13%
Clinical Feature
13%
Chronic Myeloid Leukemia
13%
Liver Cell Carcinoma
13%
Placebo-Controlled Study
13%
Hepatotoxicity
13%
Mitomycin
13%
Thalidomide
13%
Wernicke's Encephalopathy
13%
Von Willebrand Factor
13%
Bile Duct Cancer
13%
Von Willebrand Disease
13%
Simvastatin
13%
Medicine and Dentistry
Overall Survival
84%
Progression Free Survival
42%
Life Sustaining Treatment
32%
Hazard Ratio
31%
First-Line Chemotherapy
31%
Cisplatin
29%
Survival Rate
28%
Fluorouracil
28%
Adjuvant Radiotherapy
26%
Biliary Tract Cancer
26%
Janus Kinase 2
26%
Gemcitabine
26%
Recurrent Disease
24%
Prognostic Factor
23%
T Cell
21%
Adenocarcinoma
20%
Bile Duct Cancer
19%
Extrahepatic Bile Duct
19%
Advance Care Planning
19%
Advanced Cancer
19%
Randomized Controlled Trial
19%
Arm
16%
Anemia
16%
Clinical Feature
16%
Neoplasm
15%
Mucosa-Associated Lymphoid Tissue
14%
Cross Sectional Study
13%
Survivin
13%
Rare Disease
13%
Assisted Suicide
13%
Cholangiocarcinoma
13%
Germinoma
13%
Adult T-Cell Leukemia/Lymphoma
13%
Wernicke's Encephalopathy
13%
Myeloproliferative Disorder
13%
Angioimmunoblastic T-Cell Lymphoma
13%
Endodermal Sinus Tumor
13%
Pancreaticoduodenectomy
13%
CA 19-9 Antigen
13%
Docetaxel
13%
MALT Lymphoma
13%
Combination Chemotherapy
13%
Myeloproliferative Neoplasm
13%
Stomach Adenocarcinoma
13%
Von Willebrand Factor
13%
Patient Participation
13%
Medical Student
13%
Blood Clotting Factor 8
13%
Von Willebrand Disease
13%
Comorbidity
13%
Biochemistry, Genetics and Molecular Biology
Overall Survival
43%
Janus Kinase 2
26%
Disease Free Survival
21%
CD44
19%
Capecitabine
19%
Anthracycline
16%
Catenin
13%
Factor VIII
13%
Von Willebrand Factor
13%
Cancer Cell
13%
Von Willebrand Disease
13%
T Cell
13%
Receptor Tyrosine Kinase
13%
Cancer Stem Cell
13%
Survivin
13%
Survival Rate
9%
Epidermal Growth Factor Receptor
8%
Glycoprotein
7%
Phosphoinositide 3-Kinase
7%
Protein Tyrosine Phosphatase
6%
PTEN (Gene)
6%
Tyrosine Kinase
6%
Phosphatase
6%
Haemophilia A
6%
Bleeding Diathesis
6%
Circulating Tumor DNA
6%
Monoclonal Antibody
6%
Protein Expression
6%
Gene Product
6%
Tensin
6%
Randomized Controlled Trial
6%
Essential Thrombocythaemia
5%
Hormone Receptor
5%